KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short term Debt (2023 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Short term Debt for 3 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt rose 7.91% year-over-year to $9.1 million, compared with a TTM value of $9.1 million through Dec 2025, up 7.91%, and an annual FY2025 reading of $9.1 million, up 7.91% over the prior year.
  • Short term Debt was $9.1 million for Q4 2025 at Recursion Pharmaceuticals, up from $8.9 million in the prior quarter.
  • Across five years, Short term Debt topped out at $9.1 million in Q4 2025 and bottomed at $41000.0 in Q4 2023.
  • Average Short term Debt over 3 years is $7.5 million, with a median of $8.5 million recorded in 2024.
  • The sharpest move saw Short term Debt soared 20448.78% in 2024, then grew 7.91% in 2025.
  • Year by year, Short term Debt stood at $41000.0 in 2023, then skyrocketed by 20448.78% to $8.4 million in 2024, then grew by 7.91% to $9.1 million in 2025.
  • Business Quant data shows Short term Debt for RXRX at $9.1 million in Q4 2025, $8.9 million in Q3 2025, and $8.8 million in Q2 2025.